Combination Chemotherapy Principles

Overview

Most curative chemotherapy regimens use multiple drugs in combination. The rationale is rooted in tumor heterogeneity and resistance: combining agents with different mechanisms of action kills cells that might be resistant to any individual drug, while different toxicity profiles allow each drug to be used at full doses.

Principles of Drug Combination

1. Each drug should be active as a single agent: Combining ineffective drugs does not improve outcomes.
2. Non-overlapping toxicities: Allows full dosing of each drug without additive dose-limiting toxicity. Example: ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) — myelosuppression (doxorubicin, dacarbazine), pulmonary (bleomycin), neuropathy (vinblastine).
3. Different mechanisms of action: Attacks multiple tumor cell vulnerabilities simultaneously.
4. Non-cross-resistant mechanisms: Prevents pre-existing resistance from rendering the entire combination ineffective.
5. Optimal scheduling: Some combinations require specific sequencing (e.g., fluorouracil before leucovorin to maximize TS binding).

Landmark Combination Regimens

MOPP/ABVD (Hodgkin lymphoma): Established that curative intent was achievable with combination therapy. ABVD is now standard due to lower leukemia risk.

CHOP + R (NHL): Cyclophosphamide, doxorubicin, vincristine, prednisone + rituximab. Addition of rituximab (R-CHOP) dramatically improved survival in DLBCL.

FOLFOX/FOLFIRI (colorectal cancer): Folate, fluorouracil + oxaliplatin or irinotecan. Backbone of first-line colorectal cancer therapy.

BEP (testicular cancer): Bleomycin, etoposide, cisplatin — one of the most curative regimens in oncology.

Dose Intensity and Norton-Simon Model

The Norton-Simon model suggests that tumor growth follows Gompertzian kinetics; rapidly reducing tumor bulk early is most effective. Dose-dense regimens (e.g., dose-dense AC→T in breast cancer) deliver cycles every 2 weeks with G-CSF support instead of every 3 weeks, improving outcomes.

Sequencing Targeted + Cytotoxic Therapy

Concurrent targeted therapy with chemotherapy does not always improve outcomes and can antagonize cytotoxic effects. Trastuzumab + taxane is synergistic; trastuzumab + lapatinib has additive HER2 blockade. EGFR TKIs + chemotherapy in EGFR-mutant NSCLC is not superior to sequential use.

Key Takeaways

• Effective combination chemotherapy requires individually active agents with non-overlapping toxicities
• CHOP-R cures most DLBCL; BEP cures most testicular cancer — historic proof of combination principle
• Dose-dense scheduling with G-CSF support improves dose intensity without increased toxicity
• Targeted therapy + chemotherapy combinations require evidence of synergy; not all are beneficial